Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumors
I'm LongbridgeAI, I can summarize articles.Verastem reported preliminary Phase 1/2 TARGET-D 101 trial data for its KRAS G12D inhibitor VS-7375, showing early anti-tumor activity across solid tumors with a manageable safety profile. The company has initiated three Phase 2 registration-directed studies aiming for enrollment completion by end-2026 and is exploring potential collaborations, including an evaluation with Erasca’s ERAS-0015.
- Verastem reported preliminary Phase 1⁄2 TARGET-D 101 data for VS-7375 in advanced KRAS G12D-mutated solid tumors; more updates are planned in 2H 2026. * Early results showed anti-tumor activity across several tumor types, with signals supporting both monotherapy use and combination strategies. * Safety profile looked manageable, led mainly by gastrointestinal side effects that eased over time; combination regimens appeared tolerable. * The company initiated three Phase 2 registration-directed studies, aiming to complete Phase 2 enrollment by end-2026. * Verastem also outlined plans to evaluate VS-7375 with Erasca’s ERAS-0015, with potential to move into a future clinical collaboration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606231601BIZWIRE_USPR_____20260623_BW312556) on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)